当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Synthesis and Preclinical Evaluation of [18F]SiFA-PSMA Inhibitors in a Prostate Cancer Model
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2021-10-21 , DOI: 10.1021/acs.jmedchem.1c00812
Justin J Bailey 1 , Melinda Wuest 1 , Michael Wagner 1 , Atul Bhardwaj 1 , Carmen Wängler 2 , Bjoern Wängler 2 , John F Valliant 3 , Ralf Schirrmacher 1 , Frank Wuest 1
Affiliation  

Positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) with gallium-68 (68Ga) and fluorine-18 (18F) radiotracers has aroused tremendous interest over the past few years. The use of organosilicon-[18F]fluoride acceptors (SiFA) conjugated to urea-based peptidomimetic PSMA inhibitors provides a “kit-like” multidose synthesis technology. Nine novel 18F-labeled SiFA-bearing PSMA inhibitors with different linker moieties were synthesized and analyzed for their in vitro binding against [125I]I-TAAG-PSMA in LNCaP cells. IC50 values ranged from 58–570 nM. Among all compounds, [18F]SiFA-Asp2-PEG3-PSMA (IC50 = 125 nM) showed the highest tumor uptake in LNCaP tumors (SUV60min 0.73). A substantial increase in molar activity (Am) (from 7.5 ± 0.5 to 86 ± 3 GBq/μmol) led to a significant increase in LNCaP tumor uptake (SUV60min 1.18; Δ 0.45 corresponding to +62%). In vivo blocking with DCFPyL resulted in −32% uptake after 60 min. The SiFA-isotopic exchange chemistry offers a method that is readily adaptable for a “kit-type” labeling procedure and clinical translation.

中文翻译:

[18F]SiFA-PSMA 抑制剂在前列腺癌模型中的合成和临床前评估

在过去几年中,使用 gal-68 ( 68 Ga) 和 18 ( 18 F) 放射性示踪剂对前列腺特异性膜抗原 (PSMA) 进行正电子发射断层扫描 (PET) 成像引起了极大的兴趣。使用有机硅-[ 18 F] 氟化物受体 (SiFA) 与基于尿素的拟肽 PSMA 抑制剂偶联,提供了一种“类似试剂盒”的多剂量合成技术。合成了九种具有不同接头部分的新型18 F 标记的带有 SiFA 的 PSMA 抑制剂,并分析了它们在 LNCaP 细胞中对 [ 125 I] I-TAAG-PSMA 的体外结合。IC 50值范围为 58–570 nM。在所有化合物中,[ 18 F]SiFA-Asp2 -PEG 3 -PSMA (IC 50 = 125 nM) 在 LNCaP 肿瘤中显示出最高的肿瘤摄取 (SUV 60 分钟0.73)。摩尔活性(A大幅增加)(从7.5±0.5至86±3吉贝/微摩尔)导致在LNCaP肿瘤摄取一个显著增加(SUV 60分1.18;Δ0.45对应于+ 62%)。用 DCFPyL 进行体内阻断导致 60 分钟后 -32% 的吸收。SiFA 同位素交换化学提供了一种易于适用于“试剂盒类型”标记程序和临床翻译的方法。
更新日期:2021-11-11
down
wechat
bug